April 22, 2013 / 6:35 PM / 4 years ago

Consortium raises offer for 3SBio

April 22 (Reuters) - Chinese biotechnology firm 3SBio , which agreed to be taken private by a group that includes its Chief Executive Jing Lou, said the consortium raised its offer to $16.70 per American Depositary Share from $15.40.

One of the company’s top shareholders, OrbiMed Advisors, said last week that proxy advisory firm Institutional Shareholder Services recommended that 3SBio’s shareholders vote against the deal.

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below